Open AccessRecurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
Author(s) -
Chai RuiChao,
Liu Xing,
Pang Bo,
Liu YuQing,
Li JingJun,
Li YangFang,
Zhao Zheng,
Du Jiang,
Bao Zhao Shi,
Jiang Tao
Publication year - 2022
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15211
Subject(s) - lung cancer , targeted therapy , exon , exon skipping , medicine , cancer research , oncology , cancer , bioinformatics , biology , genetics , gene , alternative splicing
Identifying molecular features is an essential component of the management and targeted therapy of brain metastases (BMs). The molecular features are different between primary lung cancers and BMs of lung cancer. Here we report the DNA and RNA mutational profiles of 43 pathological samples of BMs. In addition to previously reported mutational events associated with targeted therapy, PTPRZ1‐MET , which was previously exclusively identified in glioma, was present in two cases of BMs of lung cancer. Furthermore, MET exon 14 skipping may be more common (6/37 cases) in BMs of lung cancer than the frequency previously reported in lung cancer. These findings highlight the clinical significance of targeted DNA plus RNA sequencing for BMs and suggest PTPRZ1‐MET and MET exon 14 skipping as critical molecular events that may serve as targets of targeted therapy in BMs.